Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and treated in the STEP (Safety, Tolerability and Efficacy of Progenza) trial, the first clinical trial of Progenza, the company's allogeneic stem cell product for the treatment of knee osteoarthritis.
Key highlights of the quarter included the growing demand for the company's new Turbine design and strong early demand for the Mute snoring and sleep technology. Receipts from Customers for the quarter were up $33k to $192k. Revenues from the Australian pharmacy channel will be included during the next quarter
Tissue Therapies (ASX:TIS), a biomedical technology company developing effective treatments for wound healing, today announces its intention to develop VitroGro(R) ECM as a pharmaceutical worldwide for wound healing, and approval will be concurrently sought from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Compumedics Limited (ASX:CMP) Preliminary 30 June 2015 Guidance
Reproductive Health Science Ltd (ASX:RHS) said that it has signed an exclusive distribution agreement with Medicare International Trading Limited for the sale of EmbryoCellect(TM) in China, Hong Kong and Macau. Medicare is based in Hong Kong and distributes in mainland China through its Chinese company, Miaoquan Enterprise, which is based in Shenzhen.
Compumedics Limited (ASX:CMP) is pleased to announce that the Company's Germany-based brain blood-flow Doppler ultrasonography division, Compumedics Germany GmbH (or DWL), has secured a tranche of deals totalling AU$5 million (Euro 3.7 million) over 3 years to supply its TCD systems to the German market.
Rhinomed Ltd (ASX:RNO) an Australian company focused on the development of novel nasal and respiratory technology today announced 2013 Tour de France Yellow Jersey winner Chris Froome has joined as its new Turbine(TM) Global Ambassador.
